mp.weixin.qq.com·· 20 hours agoPickScore95
OptiTROP-Lung06: Sac-TMT Plus Pembrolizumab First-Line mPFS Reaches 15.0 Months in PD-L1-Negative Advanced NSCLC
In brief
The phase 3 OptiTROP-Lung06 study showed that sac-TMT plus pembrolizumab as first-line treatment for PD-L1-negative advanced NSCLC achieved a median PFS of 15.0 months, versus 5.7 months in the control arm.
Why it matters
Head-to-head data quantify PFS and DoR differences versus immunochemotherapy and show overall survival remains at interim analysis
Source: mp.weixin.qq.com · mp.weixin.qq.com